دورية أكاديمية
A systematic review of pharmacogenetic studies on the response to biologics in patients with psoriasis.
| العنوان: | A systematic review of pharmacogenetic studies on the response to biologics in patients with psoriasis. |
|---|---|
| المؤلفون: | van Vugt LJ; Department of Dermatology, Radboud University Medical Centre, Nijmegen, the Netherlands.; Radboud Institute for Health Sciences (RIHS), Nijmegen, the Netherlands., van den Reek JMPA; Department of Dermatology, Radboud University Medical Centre, Nijmegen, the Netherlands.; Radboud Institute for Health Sciences (RIHS), Nijmegen, the Netherlands., Coenen MJH; Radboud Institute for Health Sciences (RIHS), Nijmegen, the Netherlands.; Department of Human Genetics, Radboud University Medical Centre, Nijmegen, the Netherlands., de Jong EMGJ; Department of Dermatology, Radboud University Medical Centre, Nijmegen, the Netherlands.; Radboud Institute for Health Sciences (RIHS), Nijmegen, the Netherlands.; Radboud University, Nijmegen, the Netherlands. |
| المصدر: | The British journal of dermatology [Br J Dermatol] 2018 Jan; Vol. 178 (1), pp. 86-94. Date of Electronic Publication: 2017 Dec 14. |
| نوع المنشور: | Journal Article; Systematic Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Oxford University Press Country of Publication: England NLM ID: 0004041 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2133 (Electronic) Linking ISSN: 00070963 NLM ISO Abbreviation: Br J Dermatol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2023- : Oxford : Oxford University Press Original Publication: Oxford [etc.] Published for the British Association of Dermatologists by Blackwell Scientific Publications [etc.] |
| مواضيع طبية MeSH: | Biological Products/*therapeutic use , Dermatologic Agents/*therapeutic use , Psoriasis/*drug therapy, Adalimumab/therapeutic use ; Cohort Studies ; Etanercept/therapeutic use ; Genome-Wide Association Study ; Humans ; Infliximab/therapeutic use ; Meta-Analysis as Topic ; Pharmacogenomic Testing ; Polymorphism, Genetic ; Psoriasis/genetics ; Randomized Controlled Trials as Topic ; Treatment Outcome ; Tumor Necrosis Factor-alpha/genetics ; Ustekinumab/therapeutic use |
| مستخلص: | Background: Biologics are indicated for treating moderate-to-severe psoriasis. As the number of biologics registered for the treatment of psoriasis increases, so does the need for biomarkers to guide personalized therapeutic decisions. Genetic variants might serve as predictors for treatment response, a field of research known as pharmacogenetics. Objectives: To assess which genetic variants are associated with response to biologics in patients with psoriasis according to current literature. Methods: A systematic search was performed in Embase, MEDLINE, the Cochrane Library and Web of Science. In total, 26 papers were included in this systematic review; 24 original studies and two meta-analyses. Quality was assessed using a predesigned form and risk of bias was assessed using the Newcastle-Ottawa Scale. Results: The majority of studies reported a candidate gene approach, focusing on polymorphisms in genes related to the therapeutic target or to psoriasis susceptibility. Studied populations were small and results were divergent, especially for studies investigating tumour necrosis factor inhibitors. The evidence for the role of HLA-Cw6 in ustekinumab efficacy shows minimal heterogeneity, with a higher response rate among patients who were positive for HLA-Cw6 reported across three of five studies. Conclusions: Pharmacogenetic studies in psoriasis have generated divergent results. Replication of findings in larger cohorts is required. Large-scale hypothesis-free searches for genetic biomarkers are needed to uncover the complete genetic background of outcomes for treatment with biologics. (© 2017 British Association of Dermatologists.) |
| التعليقات: | Comment in: Br J Dermatol. 2018 Jan;178(1):17. (PMID: 29357602) |
| المشرفين على المادة: | 0 (Biological Products) 0 (Dermatologic Agents) 0 (Tumor Necrosis Factor-alpha) B72HH48FLU (Infliximab) FU77B4U5Z0 (Ustekinumab) FYS6T7F842 (Adalimumab) OP401G7OJC (Etanercept) |
| تواريخ الأحداث: | Date Created: 20170625 Date Completed: 20190409 Latest Revision: 20190409 |
| رمز التحديث: | 20240628 |
| DOI: | 10.1111/bjd.15753 |
| PMID: | 28646581 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1365-2133 |
|---|---|
| DOI: | 10.1111/bjd.15753 |